Abstracts tagged "autoantibodies and salivary gland"

Abstract Number: 2426 • 2019 ACR/ARP Annual Meeting
Distinct Clinical Characteristics of Anti-Ro/SSA Negative Primary Sjögren’s Syndrome: Data from a Cohort for Sjögren’s Syndrome in Korea
Youngjae Park¹, Jennifer Lee ¹, Jung Hee Koh ², Yoon-Kyoung Sung ³, Shin-Seok Lee ⁴, Jung Yoon Choe ⁵, Seung-Cheol Shim ⁶, Ji-Min Kim ⁷, Seong-Ryul Kwon ⁸, Hyun-Ok Kim ⁹, So-Hyang Chung ¹⁰, Wan-Uk Kim ¹, Sung-Hwan Park ¹ and Seung-Ki Kwok ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Bucheon, Republic of Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁴Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ⁵Division of Rheumatology, Daegu Catholic University Medical Center, Daegu, Republic of Korea, ⁶Division of Rheumatology, Department of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital, Daejeon, Republic of Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Keimyung University Dongsan Medical Centre, Daegu, Republic of Korea, ⁸Inha University Hospital, Incheon, Republic of Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea, ¹⁰Department of Ophthalmology and Visual Science, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: To investigate clinical characteristics of patients with primary Sjögren’s syndrome (SS) who were negative for anti-Ro/SSA antibody but positive for minor salivary gland biopsy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].